Abstract: Tumor-derived cell-free DNA from the aqueous humor is assayed for diagnosis, and therapeutic prognosis of retinoblastoma demonstrating eyes with a more aggressive phenotype (with the presence of gain of 6p) and those that have a higher likelihood of responding to therapy. This also allows for evaluation of tumor response to therapy and a marker of recurrent or residual disease that requires further therapy. This method avoids direct biopsy of retinoblastoma, which is contraindicated due to risk of extraocular tumor dissemination. Somatic chromosomal copy number alterations of tumor-derived cell-free DNA provides significant prognostic value; the presence of gain of 6p was associated with a 10× increased risk of a tumor NOT responding to chemotherapy with local consolidation and requiring enucleation to cure the child of disease. AH testing also provides accurate indicators of progression of retinoblastoma and its response to therapy over the course of treatment.

Abstract: The invention relates to a method for the analysis of ovarian cancer disorders, comprising determining the genomic methylation status of one or more CpG dinucleotides in a sequence selected from the group of sequences according to SEQ ID NO. 1 to 10 and/or SEQ ID NO. 50 to SEQ ID NO. 60. Optionally, additionally following steps are performed, the one or more results from the methylation status test is input into a classifier that is obtained from a Diagnostic Multi Variate Model, calculating a likelihood as to whether the sample is from a normal tissue or an ovarian cancer tissue and/or, calculating an associated p-value for the confidence in the prediction.

Abstract: The present invention relates to a method for assisting in diagnosing breast cancer and/or monitoring breast cancer progression in a given sample based on the analysis of differential DNA methylation patterns. More particularly, the method is directed to the identification of one or more epigenetic markers that derive from the application of a variety of statistical methods in order to point out the prognostic significance of the difference in methylation states at one or more genomic loci and predict whether the sample analyzed has a good or bad prognosis following treatment.

Abstract: Provided is a method for the analysis of breast cancer disorders, comprising determining the genomic methylation status of one or more CpG dinucleotides. Furthermore, a computer program product stored on a computer-readable medium comprising software code adapted to perform the steps of the method when executed on a data-processing apparatus is provided. A device comprising means for supporting a clinician is also provided.

Abstract: Method for the analysis of breast cancer disorders, comprising determining the genomic methylation status of one or more CpG dinucleotides in a sequence selected from the group of sequences according to SEQ ID NO. 1 to 10 and/or SEQ ID NO. 50 to SEQ ID NO. 60. Optionally, additionally following steps are performed, the one or more results from the methylation status test is input into a classifier that is obtained from a Diagnostic Multi Variate Model, calculating a likelihood as to whether the sample is from a normal tissue or an breast cancer tissue and/or, calculating an associated p-value for the confidence in the prediction.

Abstract: The invention relates to a method for the analysis of ovarian cancer disorders, comprising determining the genomic methylation status of one or more CpG dinucleotides in a sequence selected from the group of sequences according to SEQ ID NO. 1 to 10 and/or SEQ ID NO. 50 to SEQ ID NO. 60. Optionally, additionally following steps are performed, the one or more results from the methylation status test is input into a classifier that is obtained from a Diagnostic Multi Variate Model, calculating a likelihood as to whether the sample is from a normal tissue or an ovarian cancer tissue and/or, calculating an associated p-value for the confidence in the prediction.

Abstract: The present invention is directed to a chlorine dioxide generation apparatus and to a method of generating chlorine dioxide utilizing this apparatus. The novel apparatus comprises a generator having a mix and dwell premix chamber interconnected with a venturi preferably, or to some other source of vacuum, undiluted reactants are permitted to mix and react in the premix chamber, prior to any dilution as by water or other fluid flowing through a venturi eductor to deliver the generated chlorine dioxide to its place of storage or utilization.